Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is ...

Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules ...

Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the ...

Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate Lumryz met all primary and key secondary ...

Pfizer and Arvinas have landed on a buyer for newly approved breast cancer med Veppanu, selling off an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and hundreds of ...

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. | As Bicara Therapeutics lines up ...

After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi ...

With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that ...

Lilly has a long association with sports, having been a major part of the Tokyo Olympics and last month's hosting of the NCAA ...